Abeona Therapeutics (ABEO) News
NASDAQ: ABEOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
2.42-0.03 (-1.22%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ABEO news summary
We found 8 recent headlines mentioning Abeona Therapeutics (ABEO): 0 in the past week and 7 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, ABEO is down 1.22% at $2.42. The most recent story, "Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences", was published by GlobeNewswire on Nov 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Abeona Therapeutics headlines
- Abeona Therapeutics® Announces Participation in Upcoming Investor ConferencesCLEVELAND, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in November…GlobeNewswire
- Abeona Therapeutics (ABEO) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaqABEO, ET
- Abeona Therapeutics Reports Q3 Net ZEVASKYN Revenue of $13.5 million and Acquisition of ABO-801Abeona Therapeutics Inc. reported its third-quarter 2026 financial results and provided an update on the commercial progress of ZEVASKYN. For the quarter ended September 30, 2026, net ZEVASKYN…Nasdaq
- Abeona Therapeutics Inc. Acquires Phase 3-Ready APT-1011 and Enters Into Agreement for $30 Million Private PlacementAbeona Therapeutics Inc. entered into an Asset Purchase Agreement on November 6, 2026, with Ellodi Pharmaceuticals, L.P. to purchase substantially all assets related to the research, development,…Nasdaq
- Abeona Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress– Q3 net ZEVASKYN revenue of $13.5 million, up 18% sequentially over Q2 –GlobeNewswire
- Abeona Therapeutics® Acquires Phase 3-Ready APT-1011, Now ABO-801, and Enters Into Agreement for $30 Million Private Placement- Adds a once-daily, oral therapy candidate for eosinophilic esophagitis with FDA Orphan Drug and Fast Track Designations –GlobeNewswire
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CLEVELAND, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity…GlobeNewswire
- Weekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Study(RTTNews) - Biotech and pharma companies delivered a busy slate of updates, spanning regulatory approvals, multibillion-dollar drug discovery partnerships and pivotal clinical-trial readouts across…NasdaqABBV, ABEO, AMRX, ANIP